CA-GILEAD-SCIENCES,-INC.
16.7.2019 22:07:11 CEST | Business Wire | Press release
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2019 financial results will be released on Tuesday, July 30, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2019 and provide a business update.
The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/ . Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 8696029 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, August 1, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the conference ID 8696029. The webcast will be archived on www.gilead.com for one year.
About Gilead
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190716005877/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
In Line With the LEAP | 28 Portfolio Rotation Strategy, Bureau Veritas Signs an Agreement to Sell Its Oil & Petrochemicals and Coal Testing and Inspection Business30.6.2026 07:30:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces that it has entered exclusive negotiations with Triton Partners regarding the sale of its Oil & Petrochemicals and Coal testing and inspection business. This strategic divestment is in full alignment with the Group’s LEAP | 28 strategy. The proposed transaction would include the Oil & Petrochemicals and Coal testing and inspection activities. In 2025, this business generated approximately EUR 450 million in revenue operating a global network across multiple countries, with a significant footprint of operational sites and employees. This business grew at a lower rate than the Group and is margin dilutive. It is included within Bureau Veritas’ “Optimize value and impact” portfolio and reported under the Agri-Food & Commodities division. The transaction supports the strategic objective to increase exposure to higher growth and margin businesses. A key milestone in LEAP | 28 portfolio rotati
Corient Accelerates European Growth With the Addition of Letus Private Office30.6.2026 07:15:00 CEST | Press release
Leading French multi-family office with approximately US$5 billion in assets is Corient’s fourth European acquisition, growing firm’s global assets to approximately US$523 billion Corient today announced an agreement to acquire Letus Private Office (“Letus”), an independent multi-family office and wealth advisory firm serving entrepreneurs, founders and other ultra-high-net-worth individuals and families across France and Europe. The acquisition, subject to closing, builds on recent transactions that have made Corient the world’s largest multi-family office and non-bank wealth manager focused on ultra-high-net worth and high-net-worth clients. Paris-based Letus was founded in 2016 and is led by Managing Partners Anice Chlagou, Stephen Lasry and Alexandre Tsouli, and Partner Sacha Levy. It manages and administers approximately €4.1 billion (about US$5 billion). Letus serves ultra-high-net worth clients, primarily entrepreneurs and their families, providing comprehensive, bespoke service
“BOCCHI THE ROCK!” SeisyunComplex Premiered on June 20!30.6.2026 07:00:00 CEST | Press release
A New Work for “TOKYO Night & Light” — Surpassing 1.4 Million Total Visitors The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625185578/en/ We are pleased to announce that the first screening of “BOCCHI THE ROCK!” SeisyunComplex, a new projection mapping work inspired by the highly popular anime “BOCCHI THE ROCK!”, was held on Saturday, June 20. Following its premiere, the work will be screened throughout the year as part of the weekday and weekend lineup of “TOKYO Night & Light”. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.4 million. As on
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease30.6.2026 07:00:00 CEST | Press release
Hengrui Pharma, a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free platform technology, announce today that on June 23, 2026, the China National Medical Products Administration (NMPA) has approved Heng Yi® (0.1% cyclosporine ophthalmic solution) for the treatment of patients with dry eye disease, aiming to increase tear secretion in patients with reduced tear production and improve the sign of the disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629052295/en/ Heng Yi Heng Yi® is the first and only water-free 0.1% cyclosporine ophthalmic solution and the second dry eye disease drug product approved in China based on the EyeSol® platform technology, following the approval of Heng Qin® (perfluorohexyloctane ophthalmic solution) in 202
Nebex Raises $30M Seed Round Led by GV to Build Market Infrastructure for the Global Space Economy29.6.2026 17:38:00 CEST | Press release
The new funding and banking relationship allow Nebex to scale the market and unlock the commercial space economy. Nebex, the market infrastructure platform for the global space economy, announced a $30M seed investment led by GV (Google Ventures), with participation from other top-tier venture funds. The company also announced a banking relationship with J.P. Morgan. The capital raise and new banking relationship will help Nebex scale its platform and connect sovereign space programs with the founders and companies building new technologies to serve the space industry. "We built Nebex because we've seen firsthand that ambitious space founders struggle to deliver complex sovereign programs due to the lack of capital markets infrastructure that supports revenue and cashflow. This is something that exists in nearly every other industry," said Tejpaul Bhatia, CEO of Nebex. "Support from these organizations gives Nebex the additional leverage and financial infrastructure to build the global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom